Trigen adds at both ends

Trigen Ltd.’s acquisition of ProCorde GmbH in a stock deal, which was to be announced this week, will allow it to integrate upstream while adding a set of preclinical compounds in the same cardiovascular space.

"We wanted to move upstream and were looking for a company targeting synergistic markets," said Sanjay Kakkar, CEO of Trigen (London, U.K.). "With ProCorde, we got biology, preclinical programs, and target discovery and validation platforms for cardiovascular diseases."...